Table 3.

Response Rates Over Time and by Sokal Risk

Variable	Patients by Imatinib Dose						P
	400 mg/d			800 mg/d
	No. With Response	No. Evaluated	% of Evaluated With Response	No. With Response	No. Evaluated	% of Evaluated With Response
MMR at time point, months
3	5	157	3.2	39	319	12.2	.001
6	27	157	17.2	107	319	33.5	.0002
9	56	157	35.7	144	319	45.1	.06
12*	63	157	40.1	148	319	46.4	.2035
MMR in evaluable patients at time point, months
3	5	137	3.6	39	283	13.8	.001
6	27	135	20.0	107	276	38.8	.001
9	56	136	41.2	144	267	53.9	.0203
12	61	133	45.9	145	269	53.9	.1386
MMR at 12 months by Sokal risk group
Low	26	62	41.9	68	135	50.4	.286
Intermediate	24	53	45.3	48	111	43.2	.867
High	11	42	26.2	29	73	39.7	.160
Cumulative incidence of CCyR by time point, months
6	70	157	44.6	181	319	56.7	.015
12	103	157	65.6	223	319	69.9	.347
CCyR by 12 months by Sokal risk group
Low	43	62	69.4	105	135	77.8	.2177
Intermediate	34	53	64.2	72	111	64.9	1.0
High	26	42	61.9	46	73	63.0	1.0

NOTE. Data are based on intent-to-treat populations unless otherwise specified.

Abbreviations: MMR, major molecular response; CCyR, complete cytogenetic response.

^*Primary end point, allowing for imputation.